These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 31562770)

  • 1. Examining the Use of Real-World Evidence in the Regulatory Process.
    Beaulieu-Jones BK; Finlayson SG; Yuan W; Altman RB; Kohane IS; Prasad V; Yu KH
    Clin Pharmacol Ther; 2020 Apr; 107(4):843-852. PubMed ID: 31562770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonrandomized Real-World Evidence to Support Regulatory Decision Making: Process for a Randomized Trial Replication Project.
    Franklin JM; Pawar A; Martin D; Glynn RJ; Levenson M; Temple R; Schneeweiss S
    Clin Pharmacol Ther; 2020 Apr; 107(4):817-826. PubMed ID: 31541454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The New FDA Real-World Evidence Program to Support Development of Drugs and Biologics.
    Klonoff DC
    J Diabetes Sci Technol; 2020 Mar; 14(2):345-349. PubMed ID: 30862182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding Use of Real-World Data and Real-World Evidence to Support Regulatory Decisions on Medical Product Effectiveness.
    Mahendraratnam N; Mercon K; Gill M; Benzing L; McClellan MB
    Clin Pharmacol Ther; 2022 Jan; 111(1):150-154. PubMed ID: 33891318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of real-world data/evidence in regulatory submissions.
    Song F; Zang C; Ma X; Hu S; Sun Q; Chow SC; Sun H
    Contemp Clin Trials; 2021 Oct; 109():106521. PubMed ID: 34339865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ISPOR, the FDA, and the Evolving Regulatory Science of Medical Device Products.
    O'Neill T; Miksad R; Miller D; Maloney L; John A; Hiller C; Hornberger J
    Value Health; 2019 Jul; 22(7):754-761. PubMed ID: 31277820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Real-World Evidence in FDA-Approved New Drug and Biologics License Applications.
    Purpura CA; Garry EM; Honig N; Case A; Rassen JA
    Clin Pharmacol Ther; 2022 Jan; 111(1):135-144. PubMed ID: 34726771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Evidence in the Real World: Beyond the FDA.
    Krause JH; Saver RS
    Am J Law Med; 2018 May; 44(2-3):161-179. PubMed ID: 30106647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
    Wu J; Wang C; Toh S; Pisa FE; Bauer L
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of real-world evidence for oncology clinical decision making in emerging economies.
    Petracci F; Ghai C; Pangilinan A; Suarez LA; Uehara R; Ghosn M
    Future Oncol; 2021 Aug; 17(22):2951-2960. PubMed ID: 34044583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comprehensive Framework for Evaluating the Value Created by Real-World Evidence for Diverse Stakeholders: The Case for Coordinated Registry Networks.
    Gressler LE; Marinac-Dabic D; Resnic FS; Williams S; Yang K; Weichold F; Avila-Tang E; Mack C; Coplan P; Panagiotou OA; Pappas G
    Ther Innov Regul Sci; 2024 Nov; 58(6):1042-1052. PubMed ID: 39060838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EA3: A softmax algorithm for evidence appraisal aggregation.
    De Pretis F; Landes J
    PLoS One; 2021; 16(6):e0253057. PubMed ID: 34138908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Real-World Evidence for Regulatory Approval and Coverage of Medical Devices: A Landscape Assessment.
    Timbie JW; Kim AY; Concannon TW
    Value Health; 2021 Dec; 24(12):1792-1798. PubMed ID: 34838277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of two assessments of real-world data and real-world evidence for regulatory decision-making.
    Yuan L; Rahman M; Concato J
    Clin Transl Sci; 2024 Jan; 17(1):e13702. PubMed ID: 38093484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making.
    Franklin JM; Glynn RJ; Martin D; Schneeweiss S
    Clin Pharmacol Ther; 2019 Apr; 105(4):867-877. PubMed ID: 30636285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018-2019.
    Eskola SM; Leufkens HGM; Bate A; De Bruin ML; Gardarsdottir H
    Clin Pharmacol Ther; 2022 Jan; 111(1):310-320. PubMed ID: 34689334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs.
    Feinberg BA; Gajra A; Zettler ME; Phillips TD; Phillips EG; Kish JK
    Value Health; 2020 Oct; 23(10):1358-1365. PubMed ID: 33032780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translational hurdles with cannabis medicines.
    Graham M; Lucas CJ; Schneider J; Martin JH; Hall W
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1325-1330. PubMed ID: 32281186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Real-World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design.
    Dagenais S; Russo L; Madsen A; Webster J; Becnel L
    Clin Pharmacol Ther; 2022 Jan; 111(1):77-89. PubMed ID: 34839524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized Clinical Trial or Real-World Evidence: How Historical Events, Public Demand, and the Resulting Laws and Regulations Shaped the Body of Medical Evidence.
    Mackowiak JI; Mack CD; Irwin DE; Zura R
    J Orthop Trauma; 2021 Mar; 35(Suppl 1):S17-S21. PubMed ID: 33587542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.